Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Assets (2020 - 2025)

Historic Assets for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $371.0 million.

  • Arcutis Biotherapeutics' Assets fell 1517.7% to $371.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $371.0 million, marking a year-over-year decrease of 1517.7%. This contributed to the annual value of $348.9 million for FY2024, which is 220.41% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Assets stood at $371.0 million for Q3 2025, which was down 1517.7% from $352.4 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Assets ranged from a high of $508.9 million in Q3 2022 and a low of $293.0 million during Q3 2023
  • Its 5-year average for Assets is $391.3 million, with a median of $379.5 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 9544.58% in 2021, then tumbled by 4243.45% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Assets (Quarter) stood at $408.2 million in 2021, then increased by 10.08% to $449.3 million in 2022, then dropped by 24.02% to $341.4 million in 2023, then rose by 2.2% to $348.9 million in 2024, then rose by 6.33% to $371.0 million in 2025.
  • Its Assets stands at $371.0 million for Q3 2025, versus $352.4 million for Q2 2025 and $344.1 million for Q1 2025.